NCT05286840View on ClinicalTrials.gov

64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

March 28, 2022

Primary Completion Date

March 28, 2023

Study Completion Date

September 30, 2023

Conditions

Prostate Cancer

Interventions

DIAGNOSTIC_TEST

64Cu-SAR-bisPSMA

Diagnostic PET/CT imaging agent targeted for Prostate Specific Membrane Antigen (PSMA)

Trial Locations (1)

68130

GU Research Network, Omaha

Sponsors

Collaborators (1)

Clarity Pharmaceuticals

All Listed Sponsors

collaborator

Clarity Pharmaceuticals

UNKNOWN

lead

Luke Nordquist, MD

OTHER